

3. (Amended) A method according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.

4. (Amended) A method according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, a norethisterone ester, levonorgestrel, progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

5. (Amended) A method according to claim 1, wherein the antigestagen component is

4-[17 β -Hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime (J 912);

4-[17 β -methoxy-17 α -(methoxymethyl)-3-oxo-estra-4,9-dien-11 β -yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime (J 1042);

4-[9 α ,10 α -epoxy-17 β -hydroxy-17 α -(methoxymethyl)-3-oxo-estr-4-en-11 β -yl]-benzaldehyde-1(E)-oxime (J 1116);

4-[17 β -methoxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime (J 867);

4-[17 β -hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime (J 956);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one (RU 38 486 - mifepristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 α -hydroxy-17 β -(3-hydroxypropyl)-13 α -methyl-gona-4,9-dien-3-one (ZK 98299 - onapristone);

Handwritten: B1

11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one (ZK 112993);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-
estra-4,9-dien-3-one (ZK 98 734 - lilopristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-
estra-4-en-3-one (ZK 137 316);


11 β -[(4-N,N-dimethylamino)-phenyl]-6 β -methyl-4',5'dihydrospiro-[estra-4,9-diene-
17,2'(3H)-furan]-3-one (ORG 31 710);

11 β -[(4-N,N-dimethylamino)-phenyl]-7 β -methyl-4',5'dihydrospiro-[estra-4,9-diene-
17,2'(3H)-furan]-3-one (ORG 31 806); or

Handwritten: E1 11 β -(4-acetylphenyl)-(3'E)-ethylidene-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3H)-furan]-
3-one (ORG 33 628).

Please cancel claim 6 in its entirety.

- Handwritten: Sub E1*
- Handwritten: B2*
7. (Amended) A method according to claim 1, wherein the GnRH-analog component is buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide or leuprolide acetate.
8. (Amended) A method according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.
9. (Amended) A method according to claim 1, wherein the testosterone-5 α -reductase-inhibitor component is finasteride, episteride, permixon, or turosteride.
10. (Amended) A method according to claim 1, wherein the α -andreno-receptor-blocker component is tolazoline, phentolamine, phenoxybenzamine, alfuzosin, or prazosin.
11. (Amended) A method according to claim 1, wherein the phosphodiesterase-inhibitor component is amrinone, milrinone, trapidil, papaverine, vesnarinone or sildenafil.



12. (Amended) A method of claim 1 wherein said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.
